*CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA®.
#Not all studies evaluated the efficacy and/or safety of CT-P13. The majority of studies were retrospective or prospective/ observational, and in most cases, CT-P13 results were compared against baseline parameters or prior evidence of Remicade®.
IBD, Inflammatory bowel disease.
PP-IFA-GBR-0306. December 2018